Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2020
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2019
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2018
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2018
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2018
Lead Product(s) : Vactosertib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2018
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2017
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : National OncoVenture
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2014
Lead Product(s) : Vactosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : National OncoVenture
Deal Size : Inapplicable
Deal Type : Inapplicable